WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BMRN

Based on 13 analysts offering 12 month price targets for Biomarin Pharmaceutical Inc

Min Forecast
$65.00+10.83%
Avg Forecast
$93.85+60.01%
Max Forecast
$126.00+114.83%

Should I buy or sell BMRN stock?

Based on 13 analysts offering ratings for Biomarin Pharmaceutical Inc.

Buy
Strong Buy
5 analysts 38.46%
Buy
3 analysts 23.08%
Hold
5 analysts 38.46%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Strong Buy" agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their BMRN stock forecasts and price targets.

BMRN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-24
lockedlocked$00.00+00.00%2025-02-20
lockedlocked$00.00+00.00%2025-02-20
lockedlocked$00.00+00.00%2025-02-20
lockedlocked$00.00+00.00%2025-02-20
UBS
Bottom 23%
23
Strong BuyMaintains$113.00+92.67%2025-02-20Find out why
Piper Sandler
Bottom 5%
5
Strong BuyMaintains$126.00+114.83%2025-02-20
Bank of America
Bottom 5%
5
Strong BuyMaintains$103.00+75.62%2025-02-20
Wolfe Research
Bottom 14%
14
BuyInitiates Coverage On$95.00+61.98%2024-11-15
Canaccord Genuity
Bottom 10%
10
HoldMaintains$84.00+43.22%2024-10-30

1 of 2

Forecast return on equity

Is BMRN forecast to generate an efficient return?

Company
N/A
Industry
153.19%
Market
81.87%

Forecast return on assets

Is BMRN forecast to generate an efficient return on assets?

Company
N/A
Industry
36.07%

BMRN earnings per share forecast

What is BMRN's earnings per share in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$3.45+53.33%
Avg 2 year Forecast
$4.55+102.14%
Avg 3 year Forecast
$4.88+116.89%
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BMRN revenue forecast

What is BMRN's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$3.1B+9.81%
Avg 2 year Forecast
$3.4B+20.2%
Avg 3 year Forecast
$3.8B+34.14%
BMRN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BMRN earnings growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?

Company
32.28%
Industry
13.28%
Market
18.17%
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BMRN revenue growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?

Company
10.05%
Industry
65.48%
Market
10.37%
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BMRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BMRN$58.65$93.85+60.01%Buy
INCY$56.80$74.36+30.91%Hold
EXEL$35.59$37.81+6.25%Buy
INSM$69.51$99.00+42.43%Strong Buy
ASND$161.15$200.70+24.54%Strong Buy
View Top Biotech Stocks

Biomarin Pharmaceutical Stock Forecast FAQ

Is Biomarin Pharmaceutical Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 13 Wall Street analysts covering (NASDAQ: BMRN) stock is to Buy BMRN stock.

Out of 13 analysts, 5 (38.46%) are recommending BMRN as a Strong Buy, 3 (23.08%) are recommending BMRN as a Buy, 5 (38.46%) are recommending BMRN as a Hold, 0 (0%) are recommending BMRN as a Sell, and 0 (0%) are recommending BMRN as a Strong Sell.

If you're new to stock investing, here's how to buy Biomarin Pharmaceutical stock.

What is BMRN's earnings growth forecast for 2025-2027?

(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual earnings growth rate of 32.28% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and it is also forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Biomarin Pharmaceutical's earnings in 2025 is $426,859,000.On average, 12 Wall Street analysts forecast BMRN's earnings for 2025 to be $658,180,829, with the lowest BMRN earnings forecast at $629,564,272, and the highest BMRN earnings forecast at $692,520,699. On average, 11 Wall Street analysts forecast BMRN's earnings for 2026 to be $867,692,188, with the lowest BMRN earnings forecast at $772,647,061, and the highest BMRN earnings forecast at $1,034,011,622.

In 2027, BMRN is forecast to generate $930,992,014 in earnings, with the lowest earnings forecast at $913,822,079 and the highest earnings forecast at $944,346,407.

What is BMRN's revenue growth forecast for 2025-2027?

(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual revenue growth rate of 10.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Biomarin Pharmaceutical's revenue in 2025 is $2,853,915,000.On average, 11 Wall Street analysts forecast BMRN's revenue for 2025 to be $597,867,427,518, with the lowest BMRN revenue forecast at $591,618,715,957, and the highest BMRN revenue forecast at $608,483,407,354. On average, 11 Wall Street analysts forecast BMRN's revenue for 2026 to be $654,449,230,263, with the lowest BMRN revenue forecast at $607,739,376,851, and the highest BMRN revenue forecast at $706,760,297,921.

In 2027, BMRN is forecast to generate $730,338,052,224 in revenue, with the lowest revenue forecast at $688,815,808,410 and the highest revenue forecast at $767,076,370,682.

What is BMRN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BMRN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is BMRN's Price Target?

According to 13 Wall Street analysts that have issued a 1 year BMRN price target, the average BMRN price target is $93.85, with the highest BMRN stock price forecast at $126.00 and the lowest BMRN stock price forecast at $65.00.

On average, Wall Street analysts predict that Biomarin Pharmaceutical's share price could reach $93.85 by Feb 24, 2026. The average Biomarin Pharmaceutical stock price prediction forecasts a potential upside of 60.01% from the current BMRN share price of $58.65.

What is BMRN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BMRN) Biomarin Pharmaceutical's current Earnings Per Share (EPS) is $2.25. On average, analysts forecast that BMRN's EPS will be $3.45 for 2025, with the lowest EPS forecast at $3.30, and the highest EPS forecast at $3.63. On average, analysts forecast that BMRN's EPS will be $4.55 for 2026, with the lowest EPS forecast at $4.05, and the highest EPS forecast at $5.42. In 2027, BMRN's EPS is forecast to hit $4.88 (min: $4.79, max: $4.95).

What is BMRN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BMRN) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.